Opt For Cancer Surgery India to Get The Best Service

Cancer treatment in India is the best option for international patients, Cancer is a disease that a large percentage of the world's population suffers from. Cancer surgery is the foundation of the treatment of cancer and involves the removal or repair of a part of the human body to diagnose or treat the disease.

They are able to get the treatment that they need from renowned oncologists and surgeons of the country. The facilities here make use of the most advanced technology to perform various types of surgery and provide their clients with treatment plans that can be found in countries like the US and UK. Every measure is taken to ensure that patients receive nothing but the best treatment. They tend to act as a friend, philosopher as well as a guide and take care of all your needs. In fact such is the prominence of these companies world wide.

One of the main reasons that global patients flock to India is the fact that the medical care services in the country are much lower than those found in other countries. Cancer surgery in India is every patient's best option as they can save a significant amount of money on medical costs while still receiving the highest quality of care from the hospital that they choose.

Another benefit of choosing India is the availability of world-class and advanced facilities. The hospitals in the country keep themselves updated to all the advancements that are made in the medical industry and make use of state-of-the-art technology and techniques to provide patients with excellent healthcare services. Patients do not have to compromise on quality although they pay very low rates for the treatments and surgeries that are available.

A wide variety of surgical treatments are available for patients who suffer from cancer. These surgeries are curative surgery, palliative surgery, reconstructive surgery, preventive surgery, cytoreductive surgery, diagnostic surgery and staging surgery. Some common procedures are cryosurgery, lumpectomy, microscopically controlled surgery, bone marrow transplant, gall bladder cancer surgery and prostate cancer surgery. A physician will recommend the surgical treatment that is most ideal for each patient's case.

Meditrina in Nagpur is the best hospital in India to get surgery for cancer. It has specialists that are skilled and experienced in providing the best surgical procedures to their patients. This hospital is renowned for the excellent services that they offer to patients from far and wide. They are able to provide their patients with different treatment options including minimally invasive procedures.

India is the world's top medical tourism destination. The medical infrastructure, facilities and equipment as well as the staff in the country's hospital are designed to make sure that international patients receive nothing but the best care and service. Patients never have to worry about negligence or unprofessionalism when they choose India as the place to get treatment. With so many benefits, it is no surprise that more people are choosing to get medical care from this country as they receive care and treatment that is unmatched anywhere else.

For more information on Cancer treatment in India, make sure and follow the link in the resource box below.

Oncology and cancer surgery hospital India is one of the best cancer treatment in India. Ajay Varma is associated with reputed medical tourism company providing World class Surgical oncology India.

View the original article here

Is Fibroid Surgery India The New Term in The Medical World?

Fibroid is such a medical syndrome which affect almost every woman at some point of time in their life. Though it must be mentioned that women in the age group of 20 to 50 years have a higher chance of having it in the first place. The chances of incidence increases all the more in case of obese as well as overweight women for sure which one compares with a women of normal weight.

Surgeons in India are renowned all over the medical circles because of their skill sets as well as the experience factor. Many of them have had their education in the premier education institutions of the country and harnessed their experience in the top hospitals of the world. The doctors along with the surgeons are trained in each and every syndrome which in a way appeals to the international patients. There is an abundant pool of doctors as well as surgeons in the country for sure. In addition to this the world class infrastructure and the facilities are supported by low costs along with the air fares being on the cheaper side. The precise reason for the low costs is that the operating costs as well as the conversion rates in terms of dollars being on the lesser side

Fibroid Surgery India is an attractive proposition for millions of international patients because of cost effective solutions. Even if all secondary expenses are taken into account like travelling, lodging the cost of performing the treatment works out to be cheaper by 60 %. Along with it with the rapid increase in the population there is an over burdence on the public health systems in the advanced countries of the world. The innocent patients become the victim of circumstances as they have to wait for a considerable amount of time waiting for their turns for the surgery to be performed.

Medical tourism has reached the summit of success. This is a long way from the times when hardly knew what the term meant. It is the process where the medical patients come to the country to avail medical treatment. In course of time it has turned out to be one of the major revenue spinners for the economy and it enjoys the active support of the government. A testimony to the fact is that even with a letter from the private clinic one can extend their duration of stay in the country by six months.

Any sort of professional help will do wonders on a foreign land and so is the case in case of medical tourism. One of the names which are renowned all over the world is Indian Med Guru which has their presence in the major cities of the country. Along with it they have an expert medical team which offers free consultation along with guidance. This works out to be a helping tool for the patients as they need to be aware of what suits them best when they come to a country like India.

Rate this Article

Is Fibroid Surgery India The New Term in The Medical World?Rating: 5.0/5 (5 votes cast)

Suhas M Jain has published 4 articles. Article submitted on April 16, 2013. Word count: 496

This article talks about some of the ways you can use the New Balance 992 running shoes

Written by: Scott Beshenich

Looking handsome and appealing is the new trend for people of all ages. For the purpose, a lot of beauty seekers today choose to refine and rejuvenate their appearance through various cosmetic surgery procedures, including face lift, neck lift, forehead lift, laser vaginal rejuvenation.

Written by: Neelam Goswami

There are two faculties of thought in regards to the new paradigm in the Legal guidelines of Quantum Physics. One is what I phone the scientific Legal guidelines of Quantum Physics. These Laws all proceed out with the Creator-not as much Large Bang theory of Chaos.

Written by: Santiago Fatchett

When you're losing weight, it can be tempting to run out and buy the new pill or the new book that promises you a quick drop in pounds.

Written by: Leigh Adams

View the original article here

Study Confirms Adding Chemotherapy To Surgery Improves Survival In Advanced Gastric Cancer

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our cancer / oncology section for the latest news on this subject. Disclaimer
Information contained in this press release was provided by the abstract's author and reflects the content of the study. It does not necessarily express ESMO's point of view

References

1. Abstracts from the 15th ESMO World Congress on Gastrointestinal Cancer are published in Annals of Oncology, Volume 24 suppls 4 June 2013 (Ann Oncol 2013 Jun; 24(Suppl 4): 5-130) http://annonc.oxfordjournals.org/content/24/suppl_4.toc

2. Abstract presentation: Thursday, 4 July 2013, 17:25 hrs, Session VII: Gastric Cancer About the ESMO World Congress on Gastrointestinal Cancer The ESMO World Congress on Gastrointestinal Cancer is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours. It has been endorsed by leading professional societies and organizations.
The ESMO 15th World Congress on Gastrointestinal Cancer has been organized in partnership with ESMO (European Society for Medical Oncology). The Congress is developed and managed by ImedexR, LLC.

ABSTRACT 0007

Adjuvant capecitabine and oxaliplatin (XELOX) for gastric cancer after D2 gastrectomy: final results from the CLASSIC trial
Sung Hoon Noh 1, Sook Ryun Park 2, Han-Kwang Yang 3, Hyun Cheol Chung 1, Ik-Joo Chung 4, Kyung Hee Lee 5, Hyung-Ho Kim 6, Jiafu Ji 7, Jen-Shi Chen 8, Yunni Lim 9, Stella Ha 9, Yung-Jue Bang 3

1 Yonsei University College of Medicine, Seodeamungyu Shinchon-dong 134, Seoul, 2 Research Institute and Hospital, National Cancer Center, Ilsandong-gu, Goyang-si Gyeonggi-do, 3 Seoul National University College of Medicine, Jongno-gu, Seoul, 4 Chonnam National University Hwasun Hospital, Hwasun-Eup, Hwasun-Gun, Jeonnam, 5 Yeungnam University College of Medicine, Nam-gu, Daegu, 6 Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 7 Beijing Cancer Hospital, Haidian, Beijing, 8 Chang Gung Memorial Hospital, Kwei-Shan Shiang, Taoyuan, 9 Roche Korea Co.,Ltd, Seocho-Gu, Seoul

Background: D2 gastrectomy, which is widely used in East Asia as the preferred surgery for patients with operable gastric cancer, is now recommended in US and European treatment guidelines for gastric cancer. Two phase III trials (ACTS-GC and CLASSIC) have been performed to assess the possible benefits of adjuvant chemotherapy after D2 surgery. ACTS-GC showed a survival benefit with fluoropyrimidine monotherapy after D2 gastrectomy compared with surgery only [Sasako et al. J Clin Oncol 2011;29:4387–93]. The CLASSIC trial compared fluoropyrimidine-oxaliplatin combination therapy (XELOX) with surgery alone; interim results showed that XELOX improved 3-year disease-free survival after D2 gastrectomy compared with surgery only [Bang et al. Lancet 2012;379:315–21]. Improved overall survival was also evident after only 3 years, but the data were immature. We report here the final results from the CLASSIC trial after a median follow-up of 5 years.

Methods: CLASSIC was a multinational open-label randomised phase III trial performed in South Korea, China, and Taiwan. Randomisation was stratified by country and disease stage. Patients with stage II–IIIB gastric cancer who had undergone curative D2 gastrectomy were assigned to adjuvant XELOX (oxaliplatin 130 mg/m2 day 1 plus capecitabine 1000 mg/m2 twice daily days 1-14 q3w) for 8 cycles or surgery alone. The primary endpoint was 3-year disease-free survival. The clinical cut-off date for the prospectively planned final 5-year efficacy analysis was 22 November 2012.

Results: At data cut-off, 103 (20%) patients in the XELOX group and 141 (27%) patients in the surgery alone group had died. This represented a 34% reduction in the risk of death with XELOX versus surgery alone (hazard ratio 0.66, 95% CI 0.51–0.85; p=0.0015 by stratified Cox regression analysis). The 5-year overall survival rate was 78% in the XELOX group and 69% in the surgery alone group (p=0.0029, log-rank test unstratified). 76 (15%) patients in the XELOX group and 135 (26%) patients in the surgery alone group received subsequent, non-protocol-specified anticancer therapies after progression of disease. In the analysis of disease-free survival, 139 (26.7%) patients in the XELOX group and 203 (39.4%) patients in the surgery alone group had relapsed, developed a new gastric cancer or died. This represented a 42% reduction in the risk of an event with XELOX versus surgery alone (hazard ratio 0.58, 95% CI 0.47–0.72; p<0.0001 by stratified Cox regression analysis). The 5-year disease-free survival rate was 68% in the XELOX group and 53% in the surgery alone group (p<0.0001, log-rank test unstratified).

Conclusion: The final analysis of the CLASSIC trial, after a median follow-up of 5 years, supports the findings from the primary analysis performed 2 years earlier. Adjuvant XELOX after curative D2 gastrectomy improves overall survival compared with surgery alone and should be considered as a standard treatment option for patients with operable gastric cancer.

ESMO

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

ESMO. "Study Confirms Adding Chemotherapy To Surgery Improves Survival In Advanced Gastric Cancer." Medical News Today. MediLexicon, Intl., 3 Jul. 2013. Web.
5 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.

View the original article here

The Many Benefits Of Robot-Assisted Kidney Cancer Surgery Do Not Include Cost

Main Category: Urology / Nephrology
Also Included In: Cancer / Oncology;??Medical Devices / Diagnostics
Article Date: 09 May 2013 - 1:00 PDT Current ratings for:
The Many Benefits Of Robot-Assisted Kidney Cancer Surgery Do Not Include Cost

Robot-assisted surgery to remove kidney cancers has seen a rapid increase in use, and has both replaced and proven safer than laparoscopic procedures for the same purpose, according to a study by the Vattikuti Urology Institute at Henry Ford Hospital in Detroit.

However, the study also shows that robotic partial nephrectomy (RPN) - while resulting in fewer complications than both open (OPN) and laparoscopic (LPN) removal of cancerous kidney tissue - also involves more "excessive" hospital charges.

"Excessive hospital charges were significantly higher with robotic partial nephrectomy," says Khurshid R. Ghani, M.D., of Vattikuti Urology Institute and lead author of the study. "While we can report no cost-savings with the procedure - quite the opposite - the benefits are obvious."

"It is a safe operation that has rapidly replaced LPN as the most common minimally invasive approach for partial nephrectomy. It has shown superior results compared to open surgery, and was better than laparoscopy in every respect but cost," he adds

The findings were presented at the annual meeting of the American Urological Association in San Diego.

Dr. Ghani says data was mined from the Nationwide Inpatient Sample (NIS), which includes inpatient discharge information from 1,044 U.S. hospitals.

Between October 2008 - when the NIS first included an identifier for robot-assisted procedures - and December 2010, the researchers found a total of 38,064 patients who underwent OPN, LPN or RPN to treat kidney cancers that had not metastasized.

Of the total, nearly 70 percent had open surgery, nearly 24 percent had robot-assisted surgery and a little more than 9 percent were treated laparoscopically.

Researchers also noted that while all three forms of kidney surgery had increased in 2010, robot-assisted partial nephrectomy soared by more than 45 percent, far overshadowing the other two types.

Complications were tracked during and after each procedure. The Henry Ford team found: Patients undergoing RPN were least likely to receive a blood transfusion, while those who had open surgery were most likely to need one. The same was true for developing complications after surgery or requiring a prolonged hospital stay. Only those undergoing RPN were less likely to develop complications during surgery.Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our urology / nephrology section for the latest news on this subject. Funding source: Henry Ford Hospital
Henry Ford Health System Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Henry Ford Health System. "The Many Benefits Of Robot-Assisted Kidney Cancer Surgery Do Not Include Cost." Medical News Today. MediLexicon, Intl., 9 May. 2013. Web.
13 May. 2013. APA

Please note: If no author information is provided, the source is cited instead.

'The Many Benefits Of Robot-Assisted Kidney Cancer Surgery Do Not Include Cost'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

View the original article here

Chemotherapy Effective Whether Given Before or After Breast Cancer Surgery

Giving chemotherapy before breast-conserving surgery is as effective against breast cancer recurrence as giving chemotherapy after breast-conserving surgery. These results were presented at the 2011 Breast Cancer Symposium.?

Breast-conserving surgery (also referred to as lumpectomy) involves removal of the breast cancer and some surrounding normal tissue. For some women, giving chemotherapy prior to surgery can shrink the cancer and make it easier to remove. There’s been some uncertainty, however, about whether chemotherapy followed by breast-conserving surgery is as effective against local-regional recurrence (cancer recurrence in or near the breast) as breast-conserving surgery followed by chemotherapy.?????

To evaluate whether risk of breast cancer recurrence varies by timing of chemotherapy, researchers collected information about roughly 3,000 women who underwent breast-conserving surgery and radiation therapy between 1987 and 2005. Roughly three-quarters of the patients underwent surgery first and the remaining patients underwent chemotherapy first. Women who received chemotherapy first tended to have cancers with worse prognostic features.????

Factors that were linked with an increased risk of breast cancer recurrence were young age (less than 50 years), clinical stage III cancer, grade 3 cancer, cancer that was estrogen receptor-negative, and close or positive surgical margins (cancer at or near the edge of the tissue that was surgically removed).?After accounting for tumor characteristics, risk of breast cancer recurrence was similar among women who underwent surgery first and women who underwent chemotherapy first.?

These results suggest that tumor characteristics—rather than the timing of chemotherapy—influence risk of breast cancer recurrence.?????

Reference: Mittendorf EA, Buchholz TA, Tucker SL et al. Impact of chemotherapy timing on local-regional failures in patients with breast cancer undergoing breast-conserving therapy. Paper presented at: 2011 Breast Cancer Symposium; September 8-10, 2011; San Francisco, CA. Abstract 82.?

Posted September 12, 2011

View the original article here